Rigel Pharmaceuticals price target lowered to $8 from $15 at Roth Capital Roth Capital lowered its target on Rigel after the company's rheumatoid arthritis treatment fostamatinib did not demonstrate equivalence versus Abbott's (ABT) Humira in a Phase II test. The firm reduced its estimates for fostamatinib but maintains a Buy rating on the stock based on valuation.
News For RIGL;ABT From The Last 14 Days
Check below for free stories on RIGL;ABT the last two weeks.
Subscribe for More Information
